Clinical and haemodynamic outcomes in 658 patients receiving the Perceval sutureless aortic valve: early results from a prospective European multicentre study (the Cavalier Trial) [ADULT CARDIAC]
CONCLUSIONS
The current 30-day results show that the Perceval valve is safe (favourable haemodynamic effect and low complication rate), and can be implanted with a fast and reproducible technique after a short learning period. Short cross-clamp and CPB times were achieved in both isolated and combined procedures. The Perceval valve represents a promising alternative to biological AVR, especially with a less invasive approach and in older patients.
Source: European Journal of Cardio-Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Laborde, F., Fischlein, T., Hakim-Meibodi, K., Misfeld, M., Carrel, T., Zembala, M., Madonna, F., Meuris, B., Haverich, A., Shrestha, M., on behalf of the Cavalier Trial Investigators, on behalf of the Cavalier Trial Investigators, Folliguet, Zannis, Pfei Tags: Basic research vascular ADULT CARDIAC Source Type: research
More News: Cardiology | Cardiovascular & Thoracic Surgery | Endocarditis | Heart | Heart Valve Surgery | Learning | Stroke | Study | Universities & Medical Training